We report the first case of recurrent ifosfamide-related neurotoxicity in the same patient following two distinct administrations of the drug at different doses and schedules and with a long interval between the two episodes. Remarkably, the first event was characterized by confusion and hallucinations, while the second, 29 months later, was characterized by partial and generalized seizures. Between the two episodes the patient had received high-dose cyclophosphamide, an oxazophoshorine agent closely related to ifosfamide, without any neurological side effects. We briefly discuss the diagnosis and management of ifosfamide-related encephalopathy.
AntmanK.H., EliasA., RyanL.: Ifosfamide and mesna: Response and toxicity at standard and high-dose schedules. Semin. Oncol., 2(Suppl. 4): 68–73, 1990.
2.
BhardwayA., BadeshaP.S.: Ifosfamide induced nonconvulsive status epilepticus. Ann. Pharmacother., 29: 1237–1239, 1995.
3.
CernyT., KupferA.: The enigma of ifosfamide encephalopathy. Ann. Oncol., 3: 679–681, 1992.
4.
DelepineL., TaillardF., DesboisF.G.: CNS side effects induced by ifosfamide-mesna in children with osteosarcoma. Biomed. Pharmacother., 40: 173–175, 1986.
5.
Di MaggioJ.R., BrownR., BaileW.F., SchapiraD.: Hallucinations and ifosfamide induced neurotoxicity. Cancer, 73: 68–73, 1994.
6.
DirixL.Y., Van OosteromA.T.: The role of ifosfamide in the teatment of sarcomas. Semin. Oncol., 16(Suppl. 3): 22–30, 1989.
7.
GieronM.A., BarakL.S., EstradaJ.: Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. J. Neurooncol., 6: 29–30, 1988.
8.
GorenM.P., WrightR.K., PrattC.B., HorowitzM.E., DodgeR.K., ViarM.J., KovnarE.H.: Potentiation of ifosfamide neurotoxicity, hematotoxicity and tubular nephrotoxicity by prior cis-diamminedichloroplatinum (II) therapy. Cancer Res., 47: 1457–1460, 1987.
9.
KupferA., AeschlimannC., WermuthB., CernyT.: Prophylaxis and reversal of ifosfamide encephalopathy with methylene blue. Lancet, 343: 763–764, 1994.
10.
KurowskiV., WagnerT.: Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde and 2-and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother. Pharmacol., 33: 36–42, 1993.
11.
LochrerP., SlodgeG.W., NicaiseC.: Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi institutional phase II trial. J. Clin. Oncol., 7: 1655–1659, 1989.
